NanoPhoria
Last verified 2026-06-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $90.2Mattributed |
|---|---|
| Latest round | series-a, $90.2M, 2025-10-01attributed |
| Founded | unknown |
| Headquarters | Modena |
| Industry | bio |
| Stage | series-a |
| Website | nanophoria.com |
NanoPhoria develops nanoparticle drug-delivery technology for inhaled treatments in respiratory and ophthalmic disease. It serves pharma partners reformulating biologics and small molecules as inhalable products. Its lipid-nanoparticle platform crosses the lung-tissue barriers where existing dry-powder inhaler tech leaves a deposition gap.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-10-01 | series-a | $90.2M | undisclosed |
Detected tech stack
bootstrap, jquery 1.11.1, jquery cdn, jquery migrate 3.4.1, mysql, nginx, parallax.js, php, plesk, wordpress 7.0
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $90.2M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $90.2M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | nanophoria.com, read 2026-06-02 |
| Description | self-reported | nanophoria.com, read 2026-06-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.